Phase III trial of Italian HIV vaccine to begin in October
BY Advocate.com Editors
August 23 2002 12:00 AM ET
Phase III testing of an experimental HIV vaccine developed by researchers at Italy's University of Milan is scheduled to begin in October, with results due in about two years, Reuters Health reports. The vaccine uses an altered form of tat, an HIV protein, to prompt an immune system response that can keep HIV replication rates under control in people already infected with the virus. It is not designed to prevent infection. The Phase III trial will involve 120 HIV-positive adults and 40 HIV-negative adults.
"So far, the results are very encouraging," said Pier Mannuci, director of the Hemophilia and Thrombosis Center at the university. "We can claim that all patients enrolled in the [previous] trials are in good condition."
The trial will mark only the second Phase III trial--the final step before submitting a compound to regulators for marketing approval--for an experimental HIV vaccine. VaxGen's AIDSVAX is the only other experimental HIV vaccine to be in final-stage testing.
- Why These Four Justices Rejected Marriage Equality
- WATCH: Mississippi Clerk Refuses to Wed Gay Couples, Quits After 24 Years
- Why Is the Duggar Family Paying the Cops Investigating Them?
- Girl Scouts Return $100K When Donor Demands It 'Not Be Used' For Trans Girls
- George Takei Takes on Clarence Thomas and Donald Trump (and Wins!)
- Texas Pastor Who Threatened to Set Himself Aflame Now 'Loves' Gays